Fate Therapeutics, Inc. (FATE)

Fate Therapeutics, Inc.'s Q·Score is 5.4/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.4× debt-to-equity). Key area to monitor: low return on equity (-56%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for FATE is $5.41, based on ratings from 9 Wall Street analysts. This is 169.9% above the current price of $2.00. Price targets are forward-looking estimates and not guarantees of future performance.

Fate Therapeutics, Inc. (FATE) scores in line with sector averages on valuation metrics. The consensus analyst price target of $5.41 is 170% above the current price.

Fate Therapeutics, Inc.'s next earnings report is expected on approximately August 11, 2026.

Fate Therapeutics, Inc. has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.

Fate Therapeutics, Inc. is reporting revenue declining 20.3% year-over-year.

Fate Therapeutics, Inc. has a debt-to-equity ratio of 0.43×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 5.85×, indicating comfortable short-term liquidity.